ImmuPharma plc (AIM:IMM)

ImmuPharma Income Statement

Financials in millions GBP. Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	-	-	0.12	0.13	0.08
Revenue Growth (YoY)	-	-	-6.57%	62.55%	-4.13%
Gross Profit	-	-	0.12	0.13	0.08
Selling, General & Admin	1.02	0.85	1.01	1.76	1.83
Research & Development	2.02	2.02	3.65	2.37	2.66
Other Operating Expenses	-0.12	-	-	-	-0.12
Operating Expenses	3.06	3.03	5.28	5.72	6.36
Operating Income	-3.06	-3.03	-5.16	-5.59	-6.28
Interest Expense	-0	-0	-0.12	-0.23	-0
Interest & Investment Income	0	0	0	0.04	0.01
Currency Exchange Gain (Loss)	-0	-0.02	0	-0.15	-0.52
Other Non Operating Income (Expenses)	-0.35	-1.41	-2.23	-1.32	0.06
EBT Excluding Unusual Items	-3.42	-4.46	-7.51	-7.25	-6.74
Other Unusual Items	-	-	-1.43	-	-
Pretax Income	-3.42	-4.46	-8.94	-7.25	-6.74
Income Tax Expense	-0.5	-0.65	-0.77	-0.39	-0.62
Net Income	-2.92	-3.81	-8.17	-6.86	-6.12
Net Income to Common	-2.92	-3.81	-8.17	-6.86	-6.12
Shares Outstanding (Basic)	362	303	251	200	153
Shares Outstanding (Diluted)	362	303	251	200	153
Shares Change (YoY)	19.51%	20.60%	25.47%	30.45%	10.53%
EPS (Basic)	-0.01	-0.01	-0.03	-0.03	-0.04
EPS (Diluted)	-0.01	-0.01	-0.03	-0.03	-0.04
Free Cash Flow	-1.36	-2.45	-4.88	-3.69	-4.33
Free Cash Flow Per Share	-0.00	-0.01	-0.02	-0.02	-0.03
Gross Margin	-	-	100.00%	100.00%	100.00%
Operating Margin	-	-	-4359.84%	-4412.70%	-8061.14%
Profit Margin	-	-	-6906.55%	-5415.72%	-7858.31%
Free Cash Flow Margin	-	-	-4126.83%	-2912.91%	-5554.70%
EBITDA	-3.03	-2.91	-5.05	-5.42	-6.19
D&A For EBITDA	0.04	0.12	0.11	0.17	0.09
EBIT	-3.06	-3.03	-5.16	-5.59	-6.28

Source: S&P Global Market Intelligence. Standard template. Financial Sources.